Ozlem Ercelep

Dr. Ozlem Ercelep

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 August 2018 in Journal of Medical Case Reports
Verified
Journal Article
Open access
PDF file
ÖAÖzkan Alan
Özkan Alan
TTTugba Akin Telli
Tugba Akin Telli
OEOzlem Ercelep
Ozlem Ercelep
ESEDA TANRIKULU SIMSEK
EDA TANRIKULU SIMSEK
TBTugba Basoglu
Tugba Basoglu
PYPerran Fulden Yumuk
Perran Fulden Yumuk
Chordoma is a rare malignant tumor of the skull base and axial skeleton, with an incidence of less than 0.1/100,000 per year. Patients with advanced chordoma have a poor prognosis due to locoregional recurrence with infiltration and destruction of surrounding bone and soft tissue. Cytotoxic chemotherapy or other systemic therapies have not been proven to be effective for these diseases. Therefore, several molecularly targeted therapies have been proposed as potentially beneficial, including tyrosine kinase inhibitors such as imatinib, sorafenib, lapatinib, and others. We present three cases of advanced chordoma treated with molecular targeted therapies: a 52-year-old Caucasian man, a 72-year-old Caucasian woman, and a 38-year-old Caucasian woman. Chordoma has few systemic treatment options and they have limited benefit. Randomized trials with large patient numbers are unfeasible in this rare disease. Targeted therapy might be a reasonable alternative treatment for chordoma. Still, new treatment strategies are needed for this rare disease.

29 November 2013 in Journal of Cancer Research and Clinical Oncology
Verified
Journal Article
Closed access
PDF file
OGOzge Gumusay
Ozge Gumusay
UCUgur Coskun
Ugur Coskun
TATülay Akman
Tülay Akman
AEAhmet Siyar Ekinci
Ahmet Siyar Ekinci
MKMuharrem Kocar
Muharrem Kocar
SBSuleyman Buyukberber
Suleyman Buyukberber

1 April 2019 in Current Problems in Cancer
Verified
Journal Article
Closed access
OEOzlem Ercelep
Ozlem Ercelep
MOMelike Ozcelik
Melike Ozcelik
MGMahmut Gumus
Mahmut Gumus

1 August 2019 in Current Problems in Cancer
Verified
Journal Article
Closed access
ÖAÖzkan Alan
Özkan Alan
TTTugba Akin Telli
Tugba Akin Telli
OEOzlem Ercelep
Ozlem Ercelep
RHRahib Hasanov
Rahib Hasanov
ESEda Tanrikulu Simsek
Eda Tanrikulu Simsek
PYPerran Fulden Yumuk
Perran Fulden Yumuk

17 March 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
NSnadiye sever
nadiye sever
FŞFatih Şimşek
Fatih Şimşek
İOİlknur Deliktaş Onur
İlknur Deliktaş Onur
HAHayati Arvas
Hayati Arvas
TGTural Guliyev
Tural Guliyev
İBİbrahim Vedat Bayoğlu
İbrahim Vedat Bayoğlu
Background: Osteosarcoma is a rare but aggressive bone malignancy. Despite advances in multimodal therapy, survival remains suboptimal, highlighting the need for prognostic markers to guide treatment. Methods: This study included 162 osteosarcoma patients who received neoadjuvant chemotherapy followed by surgery between January 2009 and March 2024. Patients received either double (cisplatin + doxorubicin) or triple (MAP or PEI) chemotherapy. Survival analyses were conducted using Kaplan–Meier curves, log-rank tests, and Cox proportional hazards models. Results: The median age was 20 years (IQR: 18–29), and 53.1% were male. Patients who received triple chemotherapy regimens demonstrated significantly longer overall survival (OS) compared to those on doublet regimens. High tumor necrosis rates (>90%) and negative surgical margins were strongly associated with improved OS, while metastatic disease at diagnosis, elevated alkaline phosphatase (ALP), and male gender were linked to poorer survival. Multivariate analysis identified adjuvant therapy, age under 18, high necrosis rate, negative margins, and normal ALP as significant OS predictors. Conclusions: Triple-agent chemotherapy, necrosis rate ≥90 and negative surgical margins are strongly associated with prolonged survival in osteosarcoma. The key prognostic indicators such as ALP levels, surgical margins and age at diagnosis should guide personalized treatment strategies to improve outcomes in curable patients.

12 May 2016 in Tumor Biology
Verified
Journal Article
Closed access
PDF file
OEOzlem Ercelep
Ozlem Ercelep
TTTurkan Ozturk Topcu
Turkan Ozturk Topcu
IBIbrahim Vedat Bayoglu
Ibrahim Vedat Bayoglu
AEAhmet Siyar Ekinci
Ahmet Siyar Ekinci
SKSinan Koca
Sinan Koca
MGMahmut Gumus
Mahmut Gumus